Custom service

Custom Antibody Labeling

Enzyme, fluorophore, biotin or gold — attached where it does not block binding.

Labels: HRP, AP, FITC — Alexa, Cy, biotin, goldDar: 1–8 — measured per lotTimeline: 1–2 weeks — including activity QC

A conjugate is a compromise between signal and binding. Label too lightly and the assay loses sensitivity; label too heavily and lysines in the CDRs are modified, the antibody aggregates, and the antigen-binding site is sterically obstructed. The work is in finding the ratio at which the conjugate performs, and in choosing chemistry that does not touch the paratope.

Random amine labelling through surface lysines is the default for HRP and most fluorophores: simple, robust, and adequate for polyclonals and for antibodies whose CDRs contain few lysines. Site-directed labelling is better where it matters — thiol coupling to hinge cysteines after mild reduction, enzymatic labelling through a genetically encoded tag, or glycan oxidation — because it keeps the label away from the binding site and gives a defined stoichiometry.

Every lot is characterised before release. Degree of labelling is measured spectrophotometrically for fluorophores and by MALDI-TOF or SEC for proteins; enzyme activity is measured against a chromogenic substrate; and the conjugate is titrated in the intended assay so that the working dilution is known rather than guessed.

Service Highlights

Where it fits

Custom labelling is used when a commercial conjugate does not exist for a clone, when the dye must match a specific laser and filter set, and when the assay demands a defined DAR — quantitative flow cytometry, for example, where the fluorescence per cell must be interpretable.

It is not a solution for a poorly performing antibody. Labelling amplifies whatever the antibody already does, including non-specific binding, and a conjugate made from a bad clone is a brighter bad clone.

Documentation and QC

Each lot is released with DAR, SEC-HPLC monomer and aggregate content, binding activity relative to the unlabelled parent, and a titration curve in the intended application. Free label is verified to be below 5% by SEC.

Frequently asked questions

Which DAR should we choose?

For flow cytometry, 2–4 dyes per IgG gives a good signal without quenching; for Western blot, HRP at 1–3 is standard; for IHC, lower labelling reduces background. We titrate rather than assume.

Can you label a Fab or a VHH?

Yes, and the lower lysine content often makes site-directed chemistry easier. For VHHs, a C-terminal cysteine or a sortase tag gives clean single-label products.

Will labelling reduce affinity?

Random lysine labelling can, if a lysine sits in or near a CDR. We compare binding before and after conjugation, and switch to a site-directed method if activity drops below 70%.

Tell us the instrument and the assay. The label and the DAR follow from that, and we will report the working dilution rather than leave you to find it.

Service Highlights

  • Chemistry matched to the label. NHS-ester for amines, maleimide for thiols, hydrazide for glycans, and streptavidin-biotin for indirect formats.
  • Site-directed options. Hinge thiol coupling, Fc-glycan labelling and tag-mediated enzymatic conjugation keep the paratope clear.
  • Measured DAR. Dye-to-protein ratio reported per lot, with the labelling reaction tuned to the application rather than to a fixed protocol.
  • Function retained. Binding ELISA compared against the unlabelled parent, with a minimum 70% retained activity for release.
  • Aggregate control. SEC-HPLC after conjugation, because cross-linked aggregates are the usual cause of high background in IHC.
  • Tandem and metal labels. PE, APC, PerCP and europium chelates for flow and TR-FRET applications.

How the work runs

  1. Label and format selection

    Application, instrument and required sensitivity decide the label. Flow cytometry, Western blot, IHC and TR-FRET each impose different constraints on DAR and on dye chemistry.

  2. Buffer exchange

    The antibody is moved into a labelling-compatible buffer free of amines, azide and carrier protein, which otherwise compete for the reactive group.

  3. Conjugation

    Molar excess of label titrated in a small pilot reaction; the ratio that gives the target DAR without aggregation is scaled up.

  4. Purification of conjugate

    Size-exclusion or affinity purification removes free dye, which otherwise produces background that cannot be blocked.

  5. Characterisation

    DAR by absorbance or MALDI-TOF, aggregation by SEC-HPLC, enzyme activity where relevant, and binding by ELISA.

  6. Application titration

    The conjugate is titrated in the intended assay and the recommended working range is reported with the lot.

Specifications & timeline

Labels
HRP, AP, FITC — Alexa, Cy, biotin, gold
Dar
1–8 — measured per lot
Timeline
1–2 weeks — including activity QC
Labels
HRP, alkaline phosphatase, FITC, Alexa Fluor 488/555/647, Cy3/Cy5, PE, APC, biotin, colloidal gold, europium
Chemistry
NHS-ester, maleimide, hydrazide, click chemistry, streptavidin bridging
DAR
Typically 2–6 for fluorophores, 1–3 for enzymes, measured per lot
Starting material
0.2–20 mg purified IgG or fragment
Timeline
1–2 weeks including pilot conjugation and QC
Deliverables
0.2–20 mg conjugate, DAR, SEC-HPLC, binding data, recommended working dilution

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.